Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.
XTalks
JANUARY 22, 2025
seroresponse rate indicating the proportion of participants achieving antibody levels above a predefined protective threshold sustained one year after vaccination. The study included 754 adolescents, comparing immune responses and safety profiles between vaccine and placebo groups. The findings reveal a remarkable 98.3%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Reporter
OCTOBER 11, 2022
Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.
Medical Xpress
APRIL 6, 2023
The human body is capable of creating a vast, diverse repertoire of antibodies—the Y-shaped sniffer dogs of the immune system that can find and flag foreign invaders. The team's findings, which have implications for our understanding of immunity and public health, are published in Science.
Bio Pharma Dive
OCTOBER 13, 2022
The findings, which were disclosed in a press release without specific data, are the first immune response results in humans for the reformulated shot targeting the BA.4 5 substrains.
Medical Xpress
MARCH 6, 2023
This also happens in our body, in driving an immune response. Like human drivers, antibodies have a "foot"—a sort of molecular limb that "presses" the gas and brake pedals. And as far as these cancer-fighting antibodies are concerned, speed is of the essence.
pharmaphorum
SEPTEMBER 7, 2020
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. All participants in the phase 2 trials (40 participants) produced antibodies against the SARS-CoV-2 spike protein.
Expert insights. Personalized for you.
261 
Let's personalize your content